By Scott Kanowsky
Sanofi announced that it had ceased negotiations and dropped a potential offer for Horizon on Sunday, saying that the expected transaction price does not meet its "value creation criteria."
Analysts at Barclays said in a note that they expect Sanofi's decision will help boost its share price in the short term. The stock had previously slipped after Horizon revealed last month that Sanofi was in the running to acquire Horizon.
Sanofi's announcement, coupled with Johnson & Johnson's (NYSE: JNJ ) choice to also scrap sales talks, leaves U.S. biotechnology giant Amgen Inc (NASDAQ: AMGN ) in pole position to buy Horizon. In a report citing a source close to the negotiations, Bloomberg News said that Amgen has already agreed to a deal valuing Horizon at about $26 billion, or around $116.5 per Horizon share.
Buying the Irish-headquartered Horizon would give Amgen a gateway to a number of lucrative treatments for rare autoimmune and inflammatory diseases, including the thyroid eye disease medicine Tepezza, which saw sales double over the last year. Revenue from this treatment is also expected to eventually top more than $4B once Horizon can secure the right to sell the drug in Europe and Japan.
Although deal activity has slowed in 2022, drugmakers have been harnessing big cash piles and a recent slide in healthcare stocks to renew their medicine pipelines through mergers and acquisitions. This year, Johnson & Johnson has inked a $16.6B deal for heart technology group Abiomed (NASDAQ: ABMD ), while Merck (NS: PROR ) & Co (NYSE: MRK ) bought blood-cancer treatment developer Imago BioSciences (NASDAQ: IMGO ) for $1.35B and Pfizer (NYSE: PFE ) snapped up biotech Biohaven Pharmaceuticals for $11.6B.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.